Biblio
Author Title [ Type] Year
Filters: First Letter Of Last Name is T and Author is Tiribelli, Mario [Clear All Filters]
ABCG2, Cytogenetic and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission. Biol Blood Marrow Transplant. 2016.
. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk Res. 2018;74:86-88.
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013.
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget. 2016.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2023.
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. Clin Lymphoma Myeloma Leuk. 2024.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.